Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.
Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), amiselimod had the highest efficacy, reports a network meta-analysis published in Neurological Sciences. S1P receptor modulators are a common treatment for MS, but their optimal therapeutic role remains elusive, noted the authors from the First Affiliated Hospital of Hainan Medical University in China.
Fingolimod, laquinimod, siponimod, ozanimod, and ponesimod also were evaluated for their effectiveness and acceptability among 13 randomized controlled trials (RCTs; 5 two-arm studies, 6 three-arm studies, 2 four-arm studies) covering 10,554 patients. Searches for RCTs published until May 2020 took place in the PubMed, Cochrane Library, Embase, and ClinicalTrials.gov databases, using multiple sclerosis or MS and s1p receptor or s1pr, s1pr1, s1pr2, s1pr3, s1pr4, or s1pr5.
“This network meta-analysis systematically evaluated the efficacy and acceptability of S1P receptors, so as to find out the most appropriate therapeutic strategy and provide a reliable basis for the prescription of S1P drugs for patients with MS,” the authors wrote.
The primary outcome was treatment efficacy at reducing the annualized relapse rate, and secondary outcomes were adverse events leading to study discontinuation. Surface under the cumulative ranking curve (SUCRA) probabilities for hierarchical clustering of interventions ranked outcomes, with smaller SUCRA values indicating better treatment measures, the authors said.
The authors’ systematic review and network meta-analysis show that the best and worst treatments were amiselimod (0.4 mg; SUCRA, 8.1%) and placebo (SUCRA, 90.5%), respectively, while ozanimod (1 mg; SUCRA, 20.4%) and ponesimod (40 mg; SUCRA, 96.0%) were the best and worst accepted interventions.
All of the patients in the included trials were 18 years and older, had an Expanded Disability Status Scale score of 1.8 or higher (on a scale of 0-10, with 0 indicating fully ambulatory and 10, death from MS), were on treatment for at least 6 months, and had an average 6-month follow-up. Of those randomized to treatments groups, most received fingolimod (n = 2619), followed by siponimod (n = 1148), laquinimod (n = 1090), ozanimod (n = 872), ponesimod (n = 337), and amiselimod (n = 312).
Laquinimod and siponimod were evaluated vs placebo at just 1 dose level each—0.6 mg and 2 mg, respectively—in all of their trials, and fingolimod, ozanimod, amiselimod, and ponesimod at various doses:
All medications were administered as oral daily doses. Adverse effects were atrioventricular block, leukoencephalopathy, elevated alanine aminotransferase, dyspnea, and infection; they were less likely in patients receiving ozanimod and most likely among those who got ponesimod and fingolimod.
Overall, although amiselimod 0.4 mg (standardized mean difference [SMD], 0.71; 95% CI, 0.59-0.86) had the highest efficacy, the 6 S1P receptors evaluated all had superior efficacy among patients with MS compared with placebo:
“The lack of head-to-head comparisons has made it impossible to compare the efficacy and acceptability of [S1P receptor modulators],” the authors wrote. “This [network meta-analysis] indicated that amiselimod (0.4 mg) is the most effective treatment strategy as a S1P receptor [modulator] for MS patients.”
They cautioned, however, that wider interpretation of their findings is limited by the potential for selective, implementation, and measurement biases; lack of a unified measure for outcome indicator reports; and most of the studies included in their analysis took place in Europe and the United States, introducing a possible difference in treatment efficacy.
Future studies should be conducted to confirm these findings.
Reference
Tong J, Zou Q, Chen Y, et al. Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. Neurol Sci. Published online February 1, 2021. doi:10.1007/s10072-021-05049-w
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More